Impact Factor 5.810 | CiteScore 6.2
More on impact ›

CORRECTION article

Front. Pharmacol., 19 March 2018 | https://doi.org/10.3389/fphar.2018.00175

Correction: The Hinge Segment of Human NADPH-Cytochrome P450 Reductase in Conformational Switching: The Critical Role of Ionic Strength

Diana Campelo1, Thomas Lautier2, Philippe Urban2, Francisco Esteves1, Sophie Bozonnet2, Gilles Truan2* and Michel Kranendonk1*
  • 1Center for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Human Toxicology, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal
  • 2LISBP, Université de Toulouse, CNRS, INRA, INSA, Toulouse, France

A correction on
The Hinge Segment of Human NADPH-Cytochrome P450 Reductase in Conformational Switching: The Critical Role of Ionic Strength

by Campelo, D., Lautier, T., Urban, P., Esteves, F., Bozonnet, S., Truan, G., et al. (2017). Front. Pharmacol. 8:755. doi: 10.3389/fphar.2017.00755

There is a mistake in the values of the y axis of Figure 1. The correct version of Figure 1 appears below. The authors apologize for the mistake. This error does not change the scientific conclusions of the article in any way.

FIGURE 1
www.frontiersin.org

Figure 1. Variation of kobs in function of the ionic strength. The activity of the soluble, WT form of human CPR was assayed with various acceptors, namely cytochrome c (A), DCPIP (B) or ferricyanide (C).

The original article has been updated.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Keywords: diflavin reductase, protein dynamics, multidomain proteins, conformational exchange, electron transfer, protein–protein interaction

Citation: Campelo D, Lautier T, Urban P, Esteves F, Bozonnet S, Truan G and Kranendonk M (2018) Correction: The Hinge Segment of Human NADPH-Cytochrome P450 Reductase in Conformational Switching: The Critical Role of Ionic Strength. Front. Pharmacol. 9:175. doi: 10.3389/fphar.2018.00175

Received: 13 February 2018; Accepted: 16 February 2018;
Published: 19 March 2018.

Edited and reviewed by: Ulrich M. Zanger, Dr. Margarete Fischer-Bosch Institut für Klinische Pharmakologie (IKP), Germany

Copyright © 2018 Campelo, Lautier, Urban, Esteves, Bozonnet, Truan and Kranendonk. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Gilles Truan, gilles.truan@insa-toulouse.fr
Michel Kranendonk, michel.kranendonk@nms.unl.pt

These authors have contributed equally to this work.